Removing belly fat before it sticks to you
UC researchers produce fat busting proteins in the laboratory
Triglycerides, those fats that seem to be the bane of any diet, remain a mystery for many researchers. Plenty of them are in Big Macs, deep pan pizza and the like, but some are a necessity to fuel the body for daily activities.
Researchers Mark Castleberry, a doctoral student, and professor Sean Davidson, both in the UC College of Medicine, have found a way to produce in the laboratory a human protein produced in the liver known as Apolipoprotein A5 (APOA 5). It plays an important role in metabolizing and clearing excess levels of triglycerides from the bloodstream.
Their findings are available in the American Society for Biochemistry and Molecular Biology’s Journal of Lipid Research online. Castleberry, who is studying in the UC Department of Molecular Genetics, Biochemistry and Microbiology, is the paper’s first author. He is shown in the photo above with Davidson.
“We are really interested in understanding triglycerides because hypertriglyceridemia — too much fat in your blood — is a big factor leading to cardiovascular disease, diabetes, obesity and other health concerns,” explains Davidson, who holds appointments in UC’s departments of Pathology and Laboratory Medicine and Molecular Genetics, Biochemistry and Microbiology. “When you have a lot of fat that is hanging around in your circulation it’s important to clear as much of it out as soon as possible.”
“APOA5 is highly involved in how fast triglycerides get taken out of your circulation,” says Davidson, who has a doctorate in biochemistry. “The more APOA5 you have the faster the triglyceride is removed. Everybody agrees it is an important protein but scientists don’t know much about its structure or how it does what it does. If we could figure out how it works we could come up with a drug that uses the same mechanism or trigger it to work better.”
The work demonstrates UC's commitment to research as described in its strategic direction called Next Lives Here.
Castleberry says researchers inserted a human gene coded by DNA into bacteria genetically engineered to produce human proteins. Once those proteins were produced they were removed from the host and purified for use in studies at the lab bench and in mouse models.
“We can quickly make a much greater amount of this protein using bacterial production than if we tried to isolate it from blood in humans,” explains Castleberry. “The mice in this study were basically fed a large bowl of fat and triglycerides.”
“We could analyze their blood after we fed them and observe the level of fat change as they digested the meal,” said Castleberry. “We were able to give our protein to the mice that had that fatty meal and rapidly clear the triglycerides that would have accumulated in their blood.”
Other co-authors of this study were Xenia Davis; Thomas Thompson, a professor in UC’s Department of Molecular Genetics, Biochemistry and Microbiology, and Patrick Tso and Min Liu, both professors in UC’s Department of Pathology and Laboratory Medicine.
The research was supported by a National Institutes of Health’s Heart, Lung and Blood Institute which funded a predoctoral fellowship for Castleberry.
All photos by Colleen Kelley/UC Creative Services
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Cincinnati Enquirer: A look inside UC's nationally-ranked co-op...
November 29, 2021
The University of Cincinnati’s co-op program rose to No. 4 in U.S. News & World Report’s latest rankings, released in mid-September this year. The local program has historically placed in the top 5 co-op programs in the country. Its reputation is enough to attract students from all over the world, reports the Cincinnati Enquirer.
Cincinnati.com: COVID-19 in Ohio: What we know so far about the...
November 29, 2021
Over the Thanksgiving weekend, the World Health Organization gave the name omicron to the newest identified version of SARS-CoV-2 and called it a variant of concern. There is still much to be learned about this latest variant and how potentially dangerous it is. In a story on the variant, Cincinnati.com interview Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine.
Medscape: New triplet regimen thought to boost melanoma...
November 29, 2021
A Medscape article features Dr. Rekha Chaudhary's comments on a new triplet therapy for metastatic melanoma patients.